Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XANAX vs CENTRAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Anxiety disorders (generalized anxiety disorder),Panic disorder with or without agoraphobia,Off-label: Premenstrual dysphoric disorder, anxiety associated with depression, chemotherapy-induced anticipatory nausea and vomiting
Treatment of anxiety disorders,Short-term relief of anxiety symptoms,Off-label: insomnia, alcohol withdrawal, muscle spasm
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
10-30 mg orally, 3-4 times daily.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Hepatic metabolism primarily via CYP3A4 to active metabolites (e.g., α-hydroxyalprazolam).
Hepatic via CYP3A4; active metabolite desmethyldiazepam (nordazepam) with long half-life.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
80% bound to albumin.
98-99% bound to albumin.
Vd: 0.71–1.26 L/kg (mean ~0.9 L/kg). Indicates moderate tissue distribution with accumulation in CNS.
1.0-2.6 L/kg (mean 1.8 L/kg); extensive tissue distribution, indicating high lipophilicity and tissue sequestration.
Oral: 80–90% (immediate-release). Rectal: ~90%. Intramuscular: ~90%.
Oral: approximately 90-100%.
No specific GFR-based guidelines; use caution in severe renal impairment (Cr Cl <30 m L/min). Consider dose reduction or increased dosing interval due to prolonged half-life. Avoid in dialysis patients due to lack of dosing studies.
GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose.
Child-Pugh Class A: No adjustment recommended. Child-Pugh Class B: Reduce dose by 50% of normal starting dose. Child-Pugh Class C: Avoid use (no established safety).
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Not approved for use in patients <18 years (safety and efficacy not established). Off-label for panic disorder in adolescents: starting dose 0.25-0.5 mg daily; titrate slowly based on response.
0.5-1 mg/kg/day in divided doses every 6-8 hours; maximum 40 mg/day.
Initiate at 0.25 mg orally 2-3 times daily (lower starting dose). Titrate cautiously due to increased sensitivity and risk of falls/cognitive impairment. Maximum recommended dose: 2 mg/day in divided doses.
Initiate at 5 mg 3-4 times daily; titrate cautiously due to increased sensitivity and risk of sedation.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.
Dependence and withdrawal reactions (including seizures) with abrupt discontinuation,Risk of abuse, misuse, and addiction,Concomitant use with CNS depressants increases risk of respiratory depression,Suicidal thinking and behavior,Activation of mania/hypomania in patients with bipolar disorder,Use in patients with narrow-angle glaucoma,Elderly and debilitated patients: increased sensitivity and risk of falls
Risk of dependence and withdrawal reactions; respiratory depression, especially with opioids; CNS depression; impaired psychomotor function; not recommended in severe hepatic impairment; use caution in elderly and debilitated patients.
Hypersensitivity to alprazolam or other benzodiazepines,Acute narrow-angle glaucoma,Concurrent use of ketoconazole or itraconazole (strong CYP3A4 inhibitors),Pregnancy (especially first trimester) and breastfeeding (risk of neonatal sedation/withdrawal)
Hypersensitivity to benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; severe hepatic impairment; children <6 months; pregnancy (especially first and third trimesters).
Grapefruit and grapefruit juice may increase serum concentrations of alprazolam; avoid concurrent use. Alcohol consumption should be avoided due to additive CNS depression. High-fat meals may delay absorption but do not significantly alter overall exposure.
Avoid grapefruit and grapefruit juice as they may increase prazepam levels. Limit caffeine intake as it may reduce sedative effects. No significant food restrictions apart from alcohol.
First trimester: Increased risk of oral clefts; second and third trimesters: Risk of floppy infant syndrome, withdrawal, and CNS depressant effects.
First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, and neonatal respiratory depression. Avoid during pregnancy, especially in first and third trimesters.
Xanax is excreted in breast milk; M/P ratio 0.36. Avoid due to potential sedative effects on the infant.
Prazepam and its active metabolite desmethyldiazepam are excreted in breast milk. M/P ratio not established. Potential for infant sedation and withdrawal. Use only if benefit outweighs risk.
Increased clearance and decreased plasma protein binding may require dose adjustment; use lowest effective dose.
Pregnancy may increase clearance of benzodiazepines; consider dose adjustment based on clinical response. No standardized regimen; avoid use if possible.
Avoid abrupt discontinuation due to risk of withdrawal seizures; taper dose by 0.5 mg every 3 days. Use with caution in elderly due to increased fall risk and cognitive impairment. Onset of action is rapid (15-30 minutes) making it suitable for panic attacks. Contraindicated in narrow-angle glaucoma and severe hepatic impairment. Monitor for respiratory depression when co-prescribed with opioids.
CENTRAX (prazepam) is a long-acting benzodiazepine with a slow onset; not ideal for acute anxiety. Use with caution in elderly due to increased risk of falls and cognitive impairment. Avoid in severe hepatic impairment; consider dose reduction in mild-to-moderate hepatic disease. Monitor for tolerance and dependence; limit to short-term use (≤4 weeks). Do not discontinue abruptly; taper to prevent withdrawal seizures.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop taking suddenly as this can cause serious withdrawal symptoms including seizures; your doctor will wean you off gradually.,Avoid alcohol and other central nervous system depressants while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness or dizziness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Store at room temperature away from moisture and heat, out of reach of children.
Avoid alcohol and other CNS depressants while taking this medication.,Do not drive or operate heavy machinery until you know how CENTRAX affects you.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking this medicine suddenly; your doctor will help you taper off.,Store at room temperature away from moisture and heat.,Report any suicidal thoughts or mood changes to your healthcare provider immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XANAX vs CENTRAX, answered by our medical review team.
XANAX is a Benzodiazepine that works by Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.. CENTRAX is a Benzodiazepine that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XANAX and CENTRAX depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XANAX is: Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.. The standard adult dose of CENTRAX is: 10-30 mg orally, 3-4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XANAX and CENTRAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XANAX is classified as Category C. First trimester: Increased risk of oral clefts; second and third trimesters: Risk of floppy infant syndrome, withdrawal, and CNS depressant effects.. CENTRAX is classified as Category C. First trimester: Data insufficient; benzodiazepines generally associated with cleft palate risk. Second and third trimesters: Risk of floppy infant syndrome, withdrawal symptoms, a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.